iTeos Therapeutics (NASDAQ:ITOS) Earns “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of iTeos Therapeutics (NASDAQ:ITOS) in a research note published on Friday morning,Benzinga reports. HC Wainwright currently has a $21.00 price target on the stock.

Separately, Wedbush reiterated an “outperform” rating and set a $25.00 target price on shares of iTeos Therapeutics in a research report on Thursday.

iTeos Therapeutics Stock Performance

ITOS opened at $7.68 on Friday. The firm has a market cap of $280.58 million, a price-to-earnings ratio of -2.44 and a beta of 1.37. The firm’s 50-day simple moving average is $8.74 and its 200-day simple moving average is $12.98. iTeos Therapeutics has a twelve month low of $7.44 and a twelve month high of $18.75.

iTeos Therapeutics (NASDAQ:ITOS) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.05) EPS for the quarter, topping analysts’ consensus estimates of ($1.18) by $0.13. As a group, sell-side analysts anticipate that iTeos Therapeutics will post -3.46 EPS for the current fiscal year.

Insider Buying and Selling

In other iTeos Therapeutics news, CFO Matthew Gall acquired 5,000 shares of iTeos Therapeutics stock in a transaction on Tuesday, November 19th. The shares were purchased at an average cost of $7.73 per share, with a total value of $38,650.00. Following the completion of the purchase, the chief financial officer now owns 65,429 shares in the company, valued at $505,766.17. The trade was a 8.27 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 12.50% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. nVerses Capital LLC grew its stake in shares of iTeos Therapeutics by 212.5% during the third quarter. nVerses Capital LLC now owns 2,500 shares of the company’s stock worth $26,000 after purchasing an additional 1,700 shares during the period. Point72 DIFC Ltd bought a new stake in shares of iTeos Therapeutics in the 3rd quarter valued at about $31,000. China Universal Asset Management Co. Ltd. raised its position in shares of iTeos Therapeutics by 60.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,024 shares of the company’s stock valued at $72,000 after acquiring an additional 2,646 shares during the period. Virtu Financial LLC bought a new stake in iTeos Therapeutics in the third quarter valued at approximately $102,000. Finally, Quest Partners LLC raised its holdings in iTeos Therapeutics by 914.7% in the third quarter. Quest Partners LLC now owns 11,020 shares of the company’s stock worth $113,000 after purchasing an additional 9,934 shares during the period. Institutional investors and hedge funds own 97.16% of the company’s stock.

iTeos Therapeutics Company Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.